Miloš Miljković Biography and Net Worth

Chief Medical Officer of Cartesian Therapeutics

Dr. Miljković is the company’s Chief Medical Officer. He is board-certified in hematology, medical oncology, and internal medicine. Prior to joining Cartesian, he was at the National Cancer Institute for over seven years, where as Staff Clinician he specialized in early-stage trials in immuno-oncology. Dr. Miljković has served as Principal Investigator on 6 clinical trials of immunotherapy and targeted agents and as Associate Investigator on more than 20 others. He completed residency at the Johns Hopkins University and Sinai Hospital of Baltimore program in internal medicine, followed by clinical and research fellowships in the joint NCI/NHLBI program at the NIH, where he also served as Chief Fellow.

What is Miloš Miljković's net worth?: The estimated net worth of Miloš Miljković is at least $244.21 thousand as of January 6th, 2025. Dr. Miljković owns 35,393 shares of Cartesian Therapeutics stock worth more than $244,212 as of December 5th. This net worth approximation does not reflect any other investments that Dr. Miljković may own. Learn More about Miloš Miljković's net worth.
How do I contact Miloš Miljković?: The corporate mailing address for Dr. Miljković and other Cartesian Therapeutics executives is 65 Grove Street, Watertown, MA 02472, United States. Cartesian Therapeutics can also be reached via phone at 617-923-1400 and via email at [email protected]. Learn More on Miloš Miljković's contact information.
Has Miloš Miljković been buying or selling shares of Cartesian Therapeutics?: Miloš Miljković has not been actively trading shares of Cartesian Therapeutics in the last ninety days. Most recently, Milos Miljkovic sold 948 shares of the business's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $16.83, for a transaction totalling $15,954.84. Following the completion of the sale, the insider now directly owns 35,393 shares of the company's stock, valued at $595,664.19. Learn More on Miloš Miljković's trading history.
Who are Cartesian Therapeutics' active insiders?: Cartesian Therapeutics' insider roster includes Blaine Davis (CFO), Miloš Miljković (Chief Medical Officer), and Timothy Springer (Director). Learn More on Cartesian Therapeutics' active insiders.
Are insiders buying or selling shares of Cartesian Therapeutics?: During the last year, insiders at the sold shares 6 times. They sold a total of 14,744 shares worth more than $247,337.42. The most recent insider tranaction occured on January, 6th when CTO Metin Kurtoglu sold 2,458 shares worth more than $41,368.14. Insiders at Cartesian Therapeutics own 60.3% of the company. Learn More about insider trades at Cartesian Therapeutics.
Information on this page was last updated on 1/6/2025.

Miloš Miljković Insider Trading History at Cartesian Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/6/2025	Sell	948	$16.83	$15,954.84	35,393
1/3/2025	Sell	932	$16.72	$15,583.04	36,341
11/14/2024	Sell	35,000	$16.13	$564,550.00	18,273

Miloš Miljković Buying and Selling Activity at Cartesian Therapeutics

Cartesian Therapeutics Company Overview

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

Today's Range

Now: $6.90

$6.53

$7.00

50 Day Range

MA: $8.43

$6.65

$10.34

2 Week Range

Now: $6.90

$5.98

$26.50

Volume

364,771 shs

Average Volume

129,291 shs

Market Capitalization

$179.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.36